На сайте Вектора об этом ничего не сказано. Да, они занимаются разработкой данной вакцины. Но о том, что они собрались ее уже испытывать официальных заявок нет. Да и кто нам скажет-то? Если получиться удачно - вот тоды мы все и узнаем.... и увесь мир тоже)))))
Я уже раньше читал где то заявления сотрудников "Вектора" о намерении приступить к клиническим испытаниям своей кандидатской вакцины. Так же кандидатская вакцина есть и у Института иммунологии - ВИЧРЕПОЛ - уже на стадии клинических испытаний. Кому интересно здесь материал по этой вакцине http://dibase.ru/article/22062009_gudimago/1
Что то еще и в Питере разрабатывают...
Но все это кандидатские вакцины... И все просят финансирование. Но, к сожалению, до реальной - превентивной или терапевтической вакцины - еще далеко. Хотя если у наших чтото получится - порадуемся за них...
На конференции в Вене этот вопрос тоже затрагивался. Пишут, что есть надежда, особенно после последних открытий антител эффективных против более 90% штампов ВИЧ.
This session provided an update on recently completed, large-scale vaccine trials. The first speaker, Merlin Robb (USA) provided an overview of RV144 outcomes, update of ongoing research efforts and productive development. RV144 results demonstrated that protection from infection is possible and this protection seems greatest in early and in low-risk mostly heterosexual participants, 90% of whom infected with HIV-1 clade E. Disinhibitional behavior was not observed during the study. No or minimal primary neutralizing antibody (NAb) response, limited T cell immunity (CD8) were observed, implying that other mechanisms of protection likely played a role. Since protection was greater early post-vaccination and in low risk participants boosting may improve it.
Two ongoing RV1444 research trials, one of which started in November 2009 deals with immunogenicity and HIV characteristics while the second trial began in May 2010 with the main goal of developing globally effective vaccines for high risk populations, Robb concluded.
The second speaker of the session, Giuseppe Pantaleo (Switzerland) underscored that T cell based vaccines will not prevent infection, but, eventually, HIV disease progression. There are number of challenges in vaccine development such as consideration of immune correlates of protection, induction of broadly NAb response, viral diversity and escape mechanism. However, T cell based vaccines have been associated with control of viral replication and protection in non-human primate (NHP) models in association with decrease viremia. He concluded his talk by underlining the importance of developing vaccine combinations that could elicit both B cell and T cell responses against HIV-1.
Seth Berkley (USA) from IAVI (International AIDS Vaccine Initiative) focused on differences in protection levels, lifetime infections and high fatality rate there represent an urgent need of vaccine development. There are certain NAb in humans and NHP infected with HIV and SIV, respectively, that are effective. Moreover, more emphasis should be given to stabilization of envelope structures, which is highly variable, and on high throughput immunogen design. Studies have shown that NAb such as VRC01 and PG1 can neutralize up to 90% of all HIV-1 isolates and hence can be considered a model for vaccine development.
Finally, Alan Bernstein (USA - Global HIV Vaccine Enterprise) underscored that we are entering very exciting HIV interventions and the main challenge is to transform the global HIV vaccine research agenda. For this we need to increase the funding, develop data for rapid sharing, bring new ideas and new minds, and only then we will be able to frame a new era of HIV vaccine research.
Что то еще и в Питере разрабатывают...
Но все это кандидатские вакцины... И все просят финансирование. Но, к сожалению, до реальной - превентивной или терапевтической вакцины - еще далеко. Хотя если у наших чтото получится - порадуемся за них...
На конференции в Вене этот вопрос тоже затрагивался. Пишут, что есть надежда, особенно после последних открытий антител эффективных против более 90% штампов ВИЧ.
This session provided an update on recently completed, large-scale vaccine trials. The first speaker, Merlin Robb (USA) provided an overview of RV144 outcomes, update of ongoing research efforts and productive development. RV144 results demonstrated that protection from infection is possible and this protection seems greatest in early and in low-risk mostly heterosexual participants, 90% of whom infected with HIV-1 clade E. Disinhibitional behavior was not observed during the study. No or minimal primary neutralizing antibody (NAb) response, limited T cell immunity (CD8) were observed, implying that other mechanisms of protection likely played a role. Since protection was greater early post-vaccination and in low risk participants boosting may improve it.
Two ongoing RV1444 research trials, one of which started in November 2009 deals with immunogenicity and HIV characteristics while the second trial began in May 2010 with the main goal of developing globally effective vaccines for high risk populations, Robb concluded.
The second speaker of the session, Giuseppe Pantaleo (Switzerland) underscored that T cell based vaccines will not prevent infection, but, eventually, HIV disease progression. There are number of challenges in vaccine development such as consideration of immune correlates of protection, induction of broadly NAb response, viral diversity and escape mechanism. However, T cell based vaccines have been associated with control of viral replication and protection in non-human primate (NHP) models in association with decrease viremia. He concluded his talk by underlining the importance of developing vaccine combinations that could elicit both B cell and T cell responses against HIV-1.
Seth Berkley (USA) from IAVI (International AIDS Vaccine Initiative) focused on differences in protection levels, lifetime infections and high fatality rate there represent an urgent need of vaccine development. There are certain NAb in humans and NHP infected with HIV and SIV, respectively, that are effective. Moreover, more emphasis should be given to stabilization of envelope structures, which is highly variable, and on high throughput immunogen design. Studies have shown that NAb such as VRC01 and PG1 can neutralize up to 90% of all HIV-1 isolates and hence can be considered a model for vaccine development.
Finally, Alan Bernstein (USA - Global HIV Vaccine Enterprise) underscored that we are entering very exciting HIV interventions and the main challenge is to transform the global HIV vaccine research agenda. For this we need to increase the funding, develop data for rapid sharing, bring new ideas and new minds, and only then we will be able to frame a new era of HIV vaccine research.